ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10 using a novel therapy for “Sepofarsen” (QR-110)
A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10 using a novel therapy for “Sepofarsen” (QR-110)